Company & Sponsor Intelligence

Hoffmann-La Roche

Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.

Request enterprise analysis →

Indexed trials24

Recruiting6

Completed10

Countries6

Therapeutic footprint

alzheimersautismmultiple_sclerosisneuro_oncologyneurodevelopmental_otherneuromuscularparkinsonsschizophrenia

Indexed studies

NCT03593590Non-interventional Study of Ocrelizumab in Participants With Relapsing or Primary Progressive Multiple Sclerosis
multiple_sclerosis · AustriaCOMPLETED

NCT01192867A Study of RO4917838 in Participants With Persistent, Predominant Negative Symptoms of Schizophrenia (NN25310)
schizophrenia · United StatesPHASE3

NCT04963270A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia Gravis
neuromuscular · United StatesPHASE3

NCT05503264A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis
neuro_oncology · United StatesPHASE3

NCT01474278A Study of RO5028442 in Adult Male High-Functioning Autistic Patients
autism · United StatesPHASE1

NCT04777331A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease
parkinsons · United StatesPHASE2

NCT04374253A Study to Evaluate the Safety, Tolerability, and Efficacy of Long-Term Gantenerumab Administration in Participants With Alzheimer's Disease (AD)
alzheimers · United StatesPHASE3

NCT04544436A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)
multiple_sclerosis · United StatesPHASE3

NCT03504917A Study of Balovaptan in Adults With Autism Spectrum Disorder With a 2-Year Open-Label Extension
autism · United StatesPHASE3

NCT07174310A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
parkinsons · United StatesPHASE3

NCT03114657A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD)
alzheimers · United StatesPHASE3

NCT05123703A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS)
multiple_sclerosis · United StatesPHASE3

Intelligence layer updated: 2026-10-14 06:11:28.884102+00:00

Enterprise intelligence

Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.

Request comparative intelligence →